Introduction {#Sec1}
============

Cyclophosphamide/total-body irradiation (CY/TBI) is a widely known conventional myeloablative regimen in allogeneic hematopoietic cell transplantation (HCT) for adult acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) \[[@CR1]--[@CR3]\], while regimens with stronger anti-leukemic effects have been sought to reduce post-transplant relapse \[[@CR4]\]. Among them, the addition of high-dose cytarabine (HDCA) to CY/TBI may be promising; in our recent large-scale study, HDCA/CY/TBI significantly improved overall survival (OS) compared to CY/TBI by suppressing relapse without increasing severe adverse events or non-relapse mortality (NRM) in cord blood transplantation (CBT) for AML/MDS \[[@CR5]\]. However, previous studies in a small cohort with mixed hematopoietic malignancies showed that HDCA/CY/TBI increased NRM after bone marrow transplantation (BMT) \[[@CR6], [@CR7]\]. These results require validation using disease-specified and newer cohorts, in order to reflect the characteristics of each malignancy and the recent progress in supportive therapies, such as antibiotics. Therefore, we performed a cohort study to compare prognosis following HDCA/CY/TBI and CY/TBI in AML/MDS patients who underwent BMT or peripheral blood stem cell transplantation (PBSCT), using the Japanese transplant registry database.

Patients and methods {#Sec2}
====================

Data for adult patients (age ≥16 years) with AML and MDS who underwent allogeneic BMT or PBSCT from related (Rel) or unrelated (UR) donors as first HCT after CY/TBI (CY, total 120 mg/kg; TBI, 10--12 Gy) or HDCA/CY/TBI (CA, 2--3 g/m^2^ twice a day for 2--3 days) \[[@CR5]\] between January 1, 2000 and December 31, 2012, were obtained from the Japanese Transplant Registry Unified Management Program (TRUMP) \[[@CR8]\]. UR-PBSCT and haploidentical HCT were not included because of the small number of patients. Donor-derived serum and/or erythrocytes were depleted from grafts in case of mismatched ABO blood type, and grafts were transplanted without T cell depletion. Our protocol complied with the Declaration of Helsinki, and it was approved by the TRUMP Data Management Committee and the Ethics Committee of Kyoto University. Each patient provided written informed consent.

From the registry database, we extracted data on basic pre-transplant characteristics and post-transplant clinical courses. Disease risk was defined as previously reported \[[@CR9]\]. Disparity in human leukocyte antigen (HLA)-A, B, and DR antigens was determined at the serologic level in Rel-BMT and Rel-PBSCT. In UR-BMT, 8 antigens including HLA-C were determined at the allele level; a 6/6 (Rel) or 8/8 (UR) match was considered HLA-matched \[[@CR10]\]. Statistical analyses were performed as described previously \[[@CR5]\].

Results {#Sec3}
=======

We evaluated 2102 patients who underwent HCT with CY/TBI (*N* = 1667) or HDCA/CY/TBI (*N* = 435), with a median follow-up of 1134 days (range, 40--4947 days). Patients with AML and high-risk disease were conditioned more frequently with HDCA/CY/TBI (Table [1](#Tab1){ref-type="table"}). The dose of TBI was not different between CY/TBI and HDCA/CY/TBI (10 Gy, 4.5 vs 4.3 %; 12 Gy, 95.1 vs 94.3 %, respectively); 12 Gy was divided into 4 (26.1 vs 34.1 %) or 6 fractions (70.2 vs 60.9 %). Graft-versus-host disease (GVHD) prophylaxis composed of cyclosporine (49.1 %) or tacrolimus (50.9 %), most of which (more than 96 %) were combined with methotrexate. No difference was observed between the two groups.Table 1Patient characteristicsVariablesTotalCY/TBIHDCA/CY/TBI*N* = 2102%*N* = 1667%*N* = 435%*p*SexMale120557.395957.524656.5Female89742.770842.518943.50.71AgeMedian (years)3838380.10(Range)(16--64)(16--62)(16--64)≤49176283.8139183.437185.3≥5034016.227616.66414.70.35PS0--1196393.3157794.638688.7≥21045.0623.7429.7Unknown351.7281.771.6\<0.01^\*^HCT-CI≤2128761.2102461.426360.5≥31115.3905.4214.8Unknown70433.555333.215134.70.78CMV sero-statusNegative39218.731218.78018.4Positive152472.4122173.330369.6Unknown1868.91348.05212.00.04^\*^DiagnosisAML180886.0139783.841194.5MDS29414.027016.2245.5\<0.01^\*^Disease riskStandard127660.7107464.420246.4High82639.359335.623353.6\<0.01^\*^ (In AML)Standard119165.999371.119848.2High61734.140428.921351.8\<0.01^\*^ (In MDS)Standard8528.98130.0416.7High20971.118970.02083.30.17Days from diagnosis to HCTMedian2392402370.03^\*^≤240105650.283450.022251.0≥241104649.883350.021349.00.71Donor sourceRel-BM45521.735121.110423.9Rel-PB49923.738623.211326.0UR-BM114854.693055.721850.10.11Graft cell doseBM (NCC, median)2.69 × 10^8^/kg2.66 × 10^8^/kg2.77 × 10^8^/kg0.27PB (CD34^+^ cell count, median)3.99× 10^6^/kg4.00× 10^6^/kg3.67× 10^6^/kg0.52HLA mismatchMatched134363.9105763.428665.7Mismatched75936.161036.614934.30.37Sex mismatchMatched114554.491955.122651.9M to F50824.239823.911025.3F to M44521.234620.89922.8Unknown40.240.200.00.45ABO mismatchMatched111453.088853.322652.0Minor38918.530518.38419.3Major35416.828717.26715.4Both1868.91488.9388.7Unknown592.8392.3204.60.12GVHD prophylaxisCyA based103349.181649.021749.9Tac based106950.985151.021850.10.73Year of HCT≤2008110752.787552.523253.3≥200999547.379247.520346.70.75Follow-up periodMedian113411301171.50.11(Range)(40--4947)(40--4922)(41--4947)*CY* cyclophosphamide, *TBI* total-body irradiation, *HDCA* high-dose cytarabine, *PS* performance status, *HCT-CI* hematopoietic cell transplant co-morbidity index, *CMV* cytomegalovirus, *AML* acute myelogenous leukemia, *MDS* myelodysplastic syndrome, *Rel* related donor, *UR* unrelated donor, *BM* bone marrow graft, *PB* peripheral blood stem cell graft, *NCC* nucleated cell count, *HLA* human leukocyte antigen, *M to F* male to female, *F to M* female to male, *GVHD* graft-versus-host disease, *CyA* cyclosporine, *Tac* tacrolimus^\*^Indicates statistically significant by the *χ* ^2^ test or Student's *t* test

OS of the HDCA/CY/TBI group was inferior to that of the CY/TBI group (Fig. [1a](#Fig1){ref-type="fig"}; 59.3 vs 72.0 % at 1 year; 45.3 vs 58.8 % at 3 years after HCT). This difference was significant on univariate analysis (Table [2](#Tab2){ref-type="table"}), but not on multivariate analysis after adjustment for confounding factors (hazard ratio (HR), 1.14; *p* = 0.13; Table [3](#Tab3){ref-type="table"}). In subgroup analyses according to pre-transplant characteristics, OS in the HDCA/CY/TBI group was significantly inferior in standard-risk disease (HR, 1.52; *p* \< 0.01). No significant differences were found in other subgroups (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Fig. 1Prognosis after HCT in each group of the conditioning regimen. **a** OS was calculated with the Kaplan-Meier method in each group of HDCA/CY/TBI and CY/TBI. HR for overall mortality of HDCA/CY/TBI compared to CY/TBI was calculated by Cox proportional hazards model after being adjusted for confounding factors such as patient sex, age, PS, CMV sero-status, diagnosis, disease risk, days from diagnosis to HCT, HLA mismatch, sex mismatch, and year of HCT. **b** Tumor-related mortality, defined as death without remission or after relapse, was calculated using Gray's method considering therapy-related death as a competing risk. HR was calculated by using Fine-Gray proportional hazards model adjusted by the confounding factors mentioned above. **c** NRM was calculated using Gray's method considering relapse as a competing risk. HR was also calculated using the same modelTable 2Univariate analysis of prognosisVariablesOverall mortalityHR(95 % CI)*p*ConditioningCY/TBI(Reference)HDCA/CY/TBI1.50(1.29--1.74)\<0.01^\*^Other variablesSexFemale(Reference)Male1.00(0.88--1.14)0.96Age≤49(Reference)≥501.93(1.65--2.25)\<0.01^\*^PS0--1(Reference)≥22.20(1.74--2.80)\<0.01^\*^HCT-CI≤2(Reference)≥31.90(1.46--2.47)\<0.01^\*^CMV sero-statusNegative(Reference)Positive1.24(1.04--1.48)0.02^\*^DiagnosisAML(Reference)MDS0.61(0.49--0.75)\<0.01^\*^Disease riskStandard(Reference)High2.38(2.10--2.71)\<0.01^\*^Days from diagnosis to HCT≤240(Reference)≥2410.89(0.78--1.01)0.08DonorRel-BM(Reference)Rel-PB1.16(0.96--1.40)0.13UR-BM1.11(0.95--1.31)0.20HLA mismatchMatched(Reference)Mismatched1.25(1.01--1.43)\<0.01^\*^Sex mismatchMatched(Reference)M to F1.04(0.89--1.22)0.60F to M1.16(0.99--1.36)0.07ABO mismatchMatched(Reference)Minor0.90(0.75--1.07)0.23Major1.11(0.93--1.32)0.23Both0.83(0.64--1.07)0.15GVHD prophylaxisCyA based(Reference)Tac based1.01(0.89--1.15)0.87Year of HCT≤2008(Reference)≥20090.86(0.75--0.99)0.04^\*^Other abbreviations are explained in Table [1](#Tab1){ref-type="table"}*HR* hazard ratio, *CI* confidence interval^\*^Indicates statistically significantTable 3Multivariate analysis of prognosis in patients with HDCA/CY/TBI compared with CY/TBIVariablesOverall mortalityTumor-related mortalityNRMHR(95 % CI)*p*HR(95 % CI)*p*HR(95 % CI)*p*ConditioningCY/TBI(Reference)(Reference)(Reference)HDCA/CY/TBI1.14(0.96--1.34)0.130.90(0.72--1.12)0.341.48(1.15--1.91)\<0.01^\*^Other variables Age≤49(Reference)(Reference)(Reference)≥501.86(1.57--2.20)\<0.01^\*^1.31(1.02--1.68)0.03^\*^2.04(1.60--2.61)\<0.01^\*^ PS0--1(Reference)(Reference)(Reference)≥21.42(1.09--1.85)\<0.01^\*^1.73(1.25--2.39)\<0.01^\*^0.71(0.41--1.23)0.22 CMV sero-statusNegative(Reference)(Reference)(Reference)Positive1.12(0.93--1.34)0.231.29(1.00--1.65)0.05^\*^0.91(0.70--1.18)0.47 DiagnosisAML(Reference)(Reference)(Reference)MDS0.40(0.32--0.51)\<0.01^\*^0.18(0.12--0.27)\<0.01^\*^1.18(0.87--1.59)0.28 Disease riskStandard(Reference)(Reference)(Reference)High2.53(2.18--2.93)\<0.01^\*^3.98(3.26--4.85)\<0.01^\*^0.97(0.77--1.23)0.82 Days from diagnosis to HCT≤240(Reference)(Reference)(Reference)≥2410.88(0.76--1.01)0.070.80(0.66--0.97)0.02^\*^0.98(0.79--1.22)0.89 HLA mismatchMatched(Reference)(Reference)(Reference)Mismatched1.25(1.08--1.44)\<0.01^\*^0.90(0.73--1.10)0.301.60(1.29--1.99)\<0.01^\*^ Sex mismatchMatched(Reference)(Reference)(Reference)M to F0.97(0.81--1.15)0.700.91(0.72--1.15)0.441.01(0.77--1.31)0.97F to M1.12(0.94--1.33)0.200.94(0.74--1.20)0.631.28(0.99--1.65)0.07 Year of HCT≤2008(Reference)(Reference)(Reference)≥20090.89(0.77--1.02)0.100.96(0.80--1.16)0.700.76(0.61--0.94)0.01^\*^Other abbreviations are explained in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}*NRM* non-relapse mortality^\*^Indicates statistically significant

Relapse, tumor-related mortality, and NRM were calculated; relapse was not reduced by HDCA addition (HR, 0.90; 95 % confidence interval (CI), 0.63--1.30; *p* = 0.58), resulting in unmitigated tumor-related mortality in the HDCA/CY/TBI group (Fig. [1b](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}) regardless of disease risk (high risk: HR, 0.91; *p* = 0.47; standard risk: HR, 0.84; *p* = 0.46). On the other hand, HDCA/CY/TBI significantly increased NRM in the whole cohort (HR, 1.48; *p* \< 0.01; Fig. [1c](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}) especially in the acute phase after HCT. The major causes of NRM included organ failure, infection, and GVHD, without significant differences between the two groups (Table [4](#Tab4){ref-type="table"}).Table 4Causes of NRMCause of NRMTotalCY/TBIHDCA/CY/TBI*N*%*N*%*N*%*p*Infection11027.37826.43229.60.52 Bacteria614318 Virus19145 Fungi1394Rejection/engraftment failure30.731.000.00.29TMA102.582.721.90.62VOD153.7124.132.80.54GVHD4410.93210.81211.10.94 Acute20146 Chronic24186Hemorrhage246.0186.165.60.84Organ failure12731.59532.23229.60.62 Liver972 Heart1385 Kidney642 CNS862 Lung826220  Interstitial pneumonia402911  ARDS14131Secondary malignancy10.210.300.00.54Others6917.14816.32119.4Total403100.0295100.0108100.0Other abbreviations are explained in Tables [1](#Tab1){ref-type="table"}--[3](#Tab3){ref-type="table"}*TMA* thrombotic microangiopathy, *VOD* veno-occlusive disease, *CNS* central nervous system, *ARDS* acute respiratory distress syndrome

We compared the clinical courses that led to higher NRM in HDCA/CY/TBI, with a focus of engraftment, GVHD, infection, and other acute phase complications (Fig. [2](#Fig2){ref-type="fig"}). The HDCA/CY/TBI group showed significantly lower proportions of neutrophil and platelet engraftment following HCT (HR, 0.80; *p* \< 0.01, and HR, 0.83; *p* \< 0.01, respectively). Complete chimerism was achieved in 78.2 % of the CY/TBI group vs 72.6 % of the HDCA/CY/TBI group (*p* = 0.04). We observed no significant differences in the incidence of acute or chronic GVHD (grades II--IV acute GVHD, 39.3 vs 38.2 %; chronic GVHD 37.5 vs 37.7 %, respectively) (Fig. [2](#Fig2){ref-type="fig"}). Hemorrhagic cystitis, mostly due to viral reactivation or infection \[[@CR11]\], and thrombotic microangiopathy (TMA) were more frequently observed in the HDCA/CY/TBI group (HR, 1.47; *p* = 0.06, and HR, 1.60; *p* = 0.04, respectively). These two complications were related to a significantly higher proportion of NRM (data not shown). Other potential complications of HDCA, such as central nervous system (CNS) dysfunction and acute respiratory dysfunction syndrome (ARDS) \[[@CR12]\], were not increased in the HDCA/CY/TBI group.Fig. 2Clinical courses after HCT in each group of CY/TBI and HDCA/CY/TBI. The cumulative incidence of major clinical events after HCT, such as engraftment, GVHD, infection, and other acute phase complications are summarized. In each event, adjusted HRs in the HDCA/CY/TBI group were analyzed in comparison with the CY/TBI group. *Dots* indicate HRs, and *bars* indicate 95 % CI ranges

Discussion {#Sec4}
==========

In this study on myeloablative BMT/PBSCT for AML/MDS, we did not observe the improvement of OS in the HDCA/CY/TBI group due to (1) a higher proportion of NRM and (2) the lack of apparent additional anti-leukemic effect of HDCA. These results differ from those of CBT, in which a stronger anti-leukemic effect without increased NRM led to superior OS in HDCA/CY/TBI \[[@CR5]\].

Among acute phase complications that can lead to NRM, hemorrhagic cystitis and TMA were increased after HDCA/CY/TBI. These complications, if not resolved early, can induce renal failure, prohibit immune reconstitution, and deteriorate patient's nutrition and performance status, which may ultimately lead to significantly higher NRM \[[@CR11], [@CR13]\]. The strong cytotoxicity of HDCA combined with significantly poorer neutrophil engraftment might cause cystitis-related virus reactivation or vascular endothelial cell injury which can induce hemorrhagic cystitis or TMA. These features were not observed in CBT \[[@CR5]\]; the relatively higher incidence of acute GVHD in BMT/PBSCT can explain this difference because both hemorrhagic cystitis and TMA are closely related to preceding acute GVHD \[[@CR11], [@CR13]\].

On the other hand, no additional anti-leukemic effect of HDCA was apparent in this study. HDCA can reduce the remaining leukemia cells that may cause relapse after HCT \[[@CR12]\]. This anti-leukemic effect of HDCA directly reduced the incidence of relapse in CBT \[[@CR5]\] because graft-versus-leukemia (GVL) effects after CBT was relatively weak \[[@CR14]\]; relapse after CBT mainly depends on the efficacy of conditioning regimens \[[@CR5]\]. In BMT/PBSCT, however, GVL effects are much stronger than CBT especially in the case of HLA-mismatched transplantation \[[@CR14]\]. Suppression of total relapse after HCT is mainly attributed to continuous GVL effects \[[@CR14]\] compared to the conditioning regimens which will be inactivated rapidly after HCT \[[@CR12]\]; strength of conditioning regimens (for example, HDCA addition in this study) may not directly influence on relapse reduction. These differences in GVL effects can partly explain the discrepancy in the efficacy of HDCA on post-transplant relapse or disease-related death.

A larger proportion of patients with high-risk disease and worse performance status in the HDCA/CY/TBI group may confound the outcomes, but multivariate and subgroup analyses indicated unimproved prognosis in HDCA/CY/TBI even after eliminating those confounding factors. Moreover, subgroup analyses regarding the percentage of myeloblast just before conditioning regimens were carried out; no significant differences of OS between CY/TBI and HDCA/CY/TBI were found in any subgroups (data not shown). The bias in regard to the HCT centers, however, still remains to be overcome in this study. The choice of conditioning regimen depends on the attending physicians in each institution, indicating that the clinical experiences of each transplant center can be a confounding factor. Unfortunately, we were not able to adjust this factor because the database did not contain such information.

The combination of granulocyte colony stimulating factor (G-CSF) with HDCA is another important topic; it is reported that G-CSF-combined HDCA/CY/TBI provided low NRM and high OS in a previous study \[[@CR15]\]. In our cohort, patients with G-CSF-combined HDCA/CY/TBI regimen (*N* = 25) revealed almost the same prognosis (HR, 1.02; 95 %CI, 0.59--1.76; *p* = 0.95) as HDCA/CY/TBI without G-CSF.

In summary, this study showed the inefficacy of adding HDCA to CY/TBI in BMT/PBSCT for AML/MDS, suggesting that the merits of HDCA in CBT cannot be extrapolated to BMT/PBSCT. Incidence of GVHD or strength of GVL effects may be related to these differences between donor sources. This single-country retrospective analysis should be validated in future prospective studies in order to determine proper conditioning regimens in BMT/PBSCT for AML/MDS.

Additional file {#Sec5}
===============

Additional file 1: Figure S1.Subgroup analyses of OS with respect to patient characteristics. OS was compared in each subgroup with respect to patient characteristics. The adjusted HRs of overall mortality in the HDCA/CY/TBI group were shown compared to the CY/TBI group. Black dots indicate HRs, and 95 %CI ranges are shown by black bars.
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